

Enzolve Technologies launches novel phenylketonuria (PKU) screening test



Dublin-based Enzolve Technologies has launched a novel newborn screening test for phenylketonuria (PKU), following the granting of the CE Mark. Enzolve's PKU test underwent extensive evaluation by the National Standards Authority of Ireland on behalf of the Irish Medicines Board prior to it being granted the CE Mark.

Phenylketonuria (PKU) is an inherited metabolic disorder that results in severe mental retardation if treatment is not started within the first few weeks of life. If the

disorder is detected early, and with a well-maintained appropriate diet, affected children can have normal development and life span. While most developed countries have programmes to screen newborns for this disorder, only 30-35 per cent of babies world-wide undergo such screening programmes.

The PKU test is the first in a suite of products, called NeoScreenPak, which Enzolve Technologies is developing to screen for a variety of metabolic disorders in babies. The company maintains that the tests are based on a single-format technology and are simpler, faster, more reliable, convenient and cost-effective than tests currently available on the market.